Inhibrx Statistics
Total Valuation
Inhibrx has a market cap or net worth of $1.82 billion. The enterprise value is $1.78 billion.
| Market Cap | 1.82B |
| Enterprise Value | 1.78B |
Important Dates
The next estimated earnings date is Tuesday, May 28, 2024, after market close.
| Earnings Date | May 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Inhibrx has 52.40 million shares outstanding. The number of shares has increased by 25.20% in one year.
| Shares Outstanding | 52.40M |
| Shares Change (YoY) | +25.20% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 17.70% |
| Owned by Institutions (%) | 73.76% |
| Float | 29.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,020.71 |
| Forward PS | n/a |
| PB Ratio | 157.32 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 997.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.82, with a Debt / Equity ratio of 18.23.
| Current Ratio | 3.82 |
| Quick Ratio | 3.56 |
| Debt / Equity | 18.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.37 |
Financial Efficiency
Return on equity (ROE) is -678.50% and return on invested capital (ROIC) is -112.06%.
| Return on Equity (ROE) | -678.50% |
| Return on Assets (ROA) | -91.70% |
| Return on Capital (ROIC) | -112.06% |
| Revenue Per Employee | $10,366 |
| Profits Per Employee | -$1.58M |
| Employee Count | 172 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Inhibrx has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.40% in the last 52 weeks. The beta is 2.88, so Inhibrx's price volatility has been higher than the market average.
| Beta (1Y) | 2.88 |
| 52-Week Price Change | +41.40% |
| 50-Day Moving Average | 34.66 |
| 200-Day Moving Average | 27.87 |
| Relative Strength Index (RSI) | 54.78 |
| Average Volume (30 Days) | 513,514 |
Short Selling Information
The latest short interest is 2.19 million, so 4.19% of the outstanding shares have been sold short.
| Short Interest | 2.19M |
| Short Previous Month | 2.20M |
| Short % of Shares Out | 4.19% |
| Short % of Float | 7.54% |
| Short Ratio (days to cover) | 5.78 |
Income Statement
In the last 12 months, Inhibrx had revenue of $1.78 million and -$271.16 million in losses. Loss per share was -$5.44.
| Revenue | 1.78M |
| Gross Profit | 1.78M |
| Operating Income | -249.28M |
| Pretax Income | -271.15M |
| Net Income | -271.16M |
| EBITDA | -235.69M |
| EBIT | -238.75M |
| Loss Per Share | -$5.44 |
Balance Sheet
The company has $252.48 million in cash and $210.89 million in debt, giving a net cash position of $41.60 million or $0.79 per share.
| Cash & Cash Equivalents | 252.48M |
| Total Debt | 210.89M |
| Net Cash | 41.60M |
| Net Cash Per Share | $0.79 |
| Equity / Book Value | 11.57M |
| Book Value Per Share | 0.22 |
| Working Capital | 202.67M |
Cash Flow
In the last 12 months, operating cash flow was -$216.42 million and capital expenditures -$5.69 million, giving a free cash flow of -$222.10 million.
| Operating Cash Flow | -216.42M |
| Capital Expenditures | -5.69M |
| Free Cash Flow | -222.10M |
| FCF Per Share | -$4.07 |
Margins
Gross margin is 100.00%, with operating and profit margins of -13,980.93% and -15,207.80%.
| Gross Margin | 100.00% |
| Operating Margin | -13,980.93% |
| Pretax Margin | -15,207.63% |
| Profit Margin | -15,207.80% |
| EBITDA Margin | -13,218.51% |
| EBIT Margin | -13,390.07% |
| FCF Margin | -12,456.76% |
Dividends & Yields
Inhibrx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.20% |
| Shareholder Yield | -25.20% |
| Earnings Yield | -14.90% |
| FCF Yield | -12.20% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 187.52% |
| EPS Growth Forecast (5Y) | -24.52% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Inhibrx has an Altman Z-Score of -1.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.3 |
| Piotroski F-Score | 2 |